It was another one of those quarters for Johnson & Johnson
Changes in currency contributed 4.7% of that growth, and when you add Pfizer's
Still, that's not too bad, considering that sales of two major brands, Procrit and Cypher, were both down more than 30% versus the year-ago quarter. Procrit and Amgen's
Compared with the third quarter, Johnson & Johnson was able to slightly increase Cypher's share of the stent market against Boston Scientific
Excluding special items like the previously announced charge for Natrecor, fourth-quarter earnings per share were $0.88, bringing the full-year non-GAAP EPS to $4.15. While it's not likely that the dollar will drop forever, shareholders can revel in J&J's year-over-year EPS growth of 10.4% in 2007 -- at least for now.
Johnson & Johnson expects 2008 earnings per share, excluding special items, to grow 6% to 7% over last year. That's not multibagger growth, but in this market, that might be enough to make it one of the best stocks of 2008.
If you'd like to see more ideas for stocks that pay dividends, grab a 30-day free trial of the Income Investor newsletter and check out all of our past recommendations.